FBLG FIBROBIOLOGICS INC.

FibroBiologics to Present at the 2025 ThinkEquity Conference

FibroBiologics to Present at the 2025 ThinkEquity Conference

HOUSTON, Oct. 14, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Founder and Chief Executive Officer, Pete O’Heeron, will present at the 2025 ThinkEquity Conference taking place October 30 at the Mandarin Oriental in New York City.

FibroBiologics will deliver a company presentation at 4:30 p.m. ET on October 30 and will be available for one-on-one investor meetings throughout the event.

For more information, please visit FibroBiologics'  or email FibroBiologics at: .

About FibroBiologics

Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 270+ US and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy and tissue regeneration. For more information, visit .

General Inquiries:

Investor Relations:

Nic Johnson

Russo Partners

(212) 845-4242

Media Contact:

Liz Phillips

Russo Partners

(347) 956-7697



EN
14/10/2025

Underlying

FBLGFIBROBIOLOGICS INC.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on FIBROBIOLOGICS INC.

 PRESS RELEASE
Free
FBLG FIBROBIOLOGICS ...

FibroBiologics Announces Pricing of $3 Million Public Offering

FibroBiologics Announces Pricing of $3 Million Public Offering HOUSTON, March 31, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced the pricing of a best efforts public offering of an aggregate of 2,272,728 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 2,2...

7h / 58m 1 EN
 PRESS RELEASE
Free
FBLG FIBROBIOLOGICS ...

FibroBiologics Announces Successful Manufacturing of CYWC628 Drug Prod...

FibroBiologics Announces Successful Manufacturing of CYWC628 Drug Product to Support Upcoming Diabetic Foot Ulcer Clinical Trial HOUSTON, March 31, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced the successful completion of manufacturing of the first batch of FibroBiologics’ proprietary CYWC628 drug product that will support ...

11h / 43m 1 EN
 PRESS RELEASE
Free
FBLG FIBROBIOLOGICS ...

FibroBiologics Announces Reverse Stock Split to Regain Compliance with...

FibroBiologics Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Bid Price Requirement Reverse Split Expected to Take Effect March 30, 2026 HOUSTON, March 25, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that its Board of Directors has approved a 1-for-20 reverse stock split of the Company’s issued and outst...

March 25, 2026 1 EN
 PRESS RELEASE
Free
FBLG FIBROBIOLOGICS ...

FibroBiologics Announces Advances in Burn Treatment Using Proprietary ...

FibroBiologics Announces Advances in Burn Treatment Using Proprietary Fibroblast Spheroid Technology HOUSTON, March 12, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using proprietary fibroblast spheroid technology, today announced the expansion of its wound care platform into the treatment of patients with acute and chronic burn injuries. Building on its investigational fibroblast spheroid-...

March 12, 2026 1 EN
 PRESS RELEASE
Free
FBLG FIBROBIOLOGICS ...

FibroBiologics Completes Site Onboarding for Phase 1/2 Clinical Trial ...

FibroBiologics Completes Site Onboarding for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers HOUSTON, March 05, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that onboarding of the clinical sites has been completed for its Phase 1/2 clinical trial evaluating the safety and efficacy of...

March 5, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch